Early, precise, and safe clinical evaluation of the pharmacodynamic effects of novel agents in the intact human tumor microenvironment

• Main Authors: Kenneth R. Gundle (Author), Karthik Rajasekaran (Author), Jeffrey Houlton (Author), Gary B. Deutsch (Author), Thomas J. Ow (Author), Robert G. Maki (Author), John Pang (Author), Cherie-Ann O. Nathan (Author), Daniel Clayburgh (Author), Jason G. Newman (Author), Elyse Brinkmann (Author), Michael J. Wagner (Author), Seth M. Pollack (Author), Matthew J. Thompson (Author), Ryan J. Li (Author), Vikas Mehta (Author), Bradley A. Schiff (Author), Barry I. Wenig (Author), Paul L. Swiecicki (Author), Alice L. Tang (Author), Jessica L. Davis (Author), Annemieke van Zante (Author), Jessica A. Bertout (Author), Wendy Jenkins (Author), Atticus Turner (Author), Marc Grenley (Author), Connor Burns (Author), Jason P. Frazier (Author), Angela Merrell (Author), Kimberly H. W. Sottero (Author), Jonathan M. J. Derry (Author), Kate C. Gillespie (Author), Bre Mills (Author), Richard A. Klinghoffer (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction: Drug development is systemically inefficient. Research and development costs for novel therapeutics average hundreds of millions to billions of dollars, with the overall likelihood of approval estimated to be as low as 6.7% for oncology drugs. Over half of these failures are due to a l...